Jpmorgan Chase & CO Aurinia Pharmaceuticals Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AUPH
# of Institutions
190Shares Held
56.5MCall Options Held
499KPut Options Held
637K-
Armistice Capital, LLC New York, NY11.1MShares$80.3 Million0.83% of portfolio
-
Black Rock Inc. New York, NY9.27MShares$66.9 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$28.6 Million2.14% of portfolio
-
State Street Corp Boston, MA2.88MShares$20.8 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.78MShares$20 Million1.94% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.02B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...